Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - trandolapril, quantity: 1 mg - capsule - excipient ingredients: maize starch; sodium stearylfumarate; povidone; lactose monohydrate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide yellow; erythrosine; gelatin - trandolapril is indicated for the treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfunction post myocardial infarction [ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2].

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - trandolapril, quantity: 0.5 mg - capsule - excipient ingredients: povidone; sodium stearylfumarate; maize starch; lactose monohydrate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; iron oxide yellow; erythrosine; gelatin - trandolapril is indicated for the treatment of hypertension. data to support the usage of trandolapril in renovascular hypertension are, at present, not available. trandolapril is also indicated for patients with left ventricular dysfunction post myocardial infarction [ejection fraction less than or equal to 35% or wmi (wall motion index) less than or equal to 1.2].

Ireland - English - HPRA (Health Products Regulatory Authority)

astrazeneca uk limited - atenolol ; nifedipine - capsules hard - 50/20 milligram - atenolol and other antihypertensives

Ireland - English - HPRA (Health Products Regulatory Authority)

abbott laboratories ireland ltd - trandolapril - capsules hard - 0.5 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

abbott laboratories ireland ltd - trandolapril - capsules hard - 1.0 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

abbott laboratories ireland ltd - trandolapril - capsules hard - 2 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - trandolapril - capsule, hard - 0.5 milligram(s) - ace inhibitors, plain; trandolapril - ace inhibitors, plain - all grades of essential hypertension; improves survival following myocardial infarction in patients with left ventricular dysfunction (ejection fraction
35 percent), with or without symptoms of heart failure and/or with or without residual ischaemia; reduces significantly the overall mortality, especially from cardiovascular mortality. it significantly decreases the risk of sudden death and the occurrence of severe or resistant heart failure, and tends to decrease the incidence of fatal and non-fatal reinfarctions.

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - trandolapril - capsule, hard - 1.0 milligram(s) - ace inhibitors, plain; trandolapril - ace inhibitors, plain - all grades of essential hypertension; improves survival following myocardial infarction in patients with left ventricular dysfunction (ejection fraction
35 percent), with or without symptoms of heart failure and/or with or without residual ischaemia; reduces significantly the overall mortality, especially from cardiovascular mortality. it significantly decreases the risk of sudden death and the occurrence of severe or resistant heart failure, and tends to decrease the incidence of fatal and non-fatal reinfarctions

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - trandolapril - capsule, hard - 2 milligram(s) - ace inhibitors, plain; trandolapril - ace inhibitors, plain - all grades of essential hypertension; k improves survival following myocardial infarction in patients with left ventricular dysfunction (ejection fraction
35 percent), with or without symptoms of heart failure and/or with or without residual ischaemia; reduces significantly the overall mortality, especially from cardiovascular mortality. it significantly decreases the risk of sudden death and the occurrence of severe or resistant heart failure, and tends to decrease the incidence of fatal and non-fatal reinfarctions

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - diltiazem hydrochloride - modified-release capsule - 90mg